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Abstract 
Introduction: The pathophysiology of diabetic macular edema (DME) is complex, 
involving vascular endothelial growth factor (VEGF) and other inflammatory mediators. 
DME is currently treated first-line with intravitreal anti-VEGF treatments, though some 
cases are refractory to multiple anti-VEGF treatments. 
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2Areas Covered: This article examines the evolution of treatment practices for DME, with 
discussion of the recent studies that guide treatment for refractory cases of DME. A 
literature search was performed using the following terms: anti-VEGF, DME, aflibercept, 
bevacizumab, ranibizumab, refractory macular edema, and VEGF. 
Expert Opinion: Focal extrafoveal DME may be treated first-line with laser. In patients 
with center-involving DME and only mild vision loss, consider starting treatment with 
bevacizumab, especially when cost is an issue, whereas aflibercept may be considered 
more strongly in patients with moderate visual loss or worse. There are no standard 
protocols that define “treatment failure,” but several studies have reported that switching 
from bevacizumab to either ranibizumab or aflibercept will result in further reduction of 
CSFT and improvement in BCVA. Further study with prospective randomized trials is 
warranted to validate these findings. Switching to intravitreal corticosteroids may be of 
particular benefit to pseudophakic patients. Anti-VEGF combination with sustained-
release corticosteroids also appears promising for refractory DME. 
Keywords: aflibercept, Avastin, bevacizumab, dexamethasone, diabetic macular edema, 
DME, Eylea, fluocinolone acetonide, Iluvien, ranibizumab, Lucentis, Ozurdex, VEGF 
1. Introduction
Diabetic macular edema (DME) is a leading cause of blindness in the working-
age population of most developed countries [1]. The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy showed that the ten-year rate of developing DME in the US was 
20.1% among Type I diabetics, 25.4% among insulin-dependent Type II diabetics, and 
313.9% for non-insulin dependent Type II diabetics [2]. Nearly half of those developing 
DME will lose two or more lines of visual acuity within two years [3]. 
Macular laser photocoagulation, which had traditionally been standard treatment 
for DME since the Early Treatment Diabetic Retinopathy Study (ETDRS), slows the rate 
of vision loss and helps stabilize vision, but has demonstrated only limited ability to 
restore lost vision [4]. Intravitreal medications targeted toward vascular endothelial 
growth factor (VEGF) have become first line therapy in DME patients.  These 
medications bind VEGF, thereby decreasing angiogenesis and vascular permeability, 
causing regression of diabetic neovascularization and reduction in DME respectively [1, 
5]. Several recent clinical trials suggest that these therapies are more effective for DME 
than laser therapy [6-13].   
2. Pathophysiology of DME
Chronic hyperglycemia contributes to alterations in the structural and cellular 
components of retinal microvasculature. Early on, there is damage to the pericytes that 
are responsible for regulating capillary perfusion, which results in microaneurysm 
formation and impaired regulation of retinal blood flow [14]. Damage to endothelial cells 
that are responsible for maintaining the blood-retinal barrier allows for accumulation of 
extracellular fluid in the macula. There is also thickening of the capillary basement 
membrane and increased deposition of extracellular matrix components [1, 14, 15]. Over 
time, continued retinal microvasculature damage results in capillary nonperfusion and 
retinal ischemia, resulting in upregulation of angiogenic factors, such as vascular 
endothelial growth factor (VEGF) [5].   
4VEGF plays a key role not only in angiogenesis, but also in vascular permeability 
[16]. There are several different VEGF isoforms due to the alternative splicing and 
include VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E, and placental growth 
factor (PLGF). The actions of VEGF family members are mediated by the activation of 
tyrosine kinase receptors.  The VEGF receptors (VEGFR) have seven immunoglobulin–
like loops in their extra cellular domain and a kinase insert region in the intracellular 
domain. VEGFRs can signal via mitogen-activating protein kinase (MAPK) signaling 
pathway or through elevation in intracellular calcium concentration in endothelial cell 
forming the vessel walls [17].  
VEGF-A is a critical regulator of ocular angiogenesis and vascular permeability.  
VEGF-A acts at VEGFR 1 and 2.  VEGFR1 (fms-like tyrosine kinase-1) has both positive 
and negative angiogenic effects; VEGFR2 (fetal liver kinase-1 and kinase insert domain-
containing receptor) is the primary mediator of the mitogenic, angiogenic and vascular 
permeability effects of VEGF-A [16]. VEGF mediates angiogenesis by promoting 
endothelial cell (EC) migration, proliferation, and survival. VEGF also possesses 
inflammatory properties through its capacity to mediate microvascular permeability and 
increase adhesion of leukocytes. VEGF was found to stimulate expression of intracellular 
adhesion molecule -1 (ICAM-1) and vascular cell adhesion molecule -1 (VCAM-1) [18], 
thus incorporating the inflammatory cascade, initiating early diabetic retinal leukocyte 
adhesion and aiding the development of diabetic vasculopathy.  
Inflammation plays an important role in the pathogenesis of DME, in which there 
is upregulation of prostaglandins and other inflammatory mediators, such as tumor 
5necrosis factor-alpha, cyclooxegenase-2, and interleukin-6, interleukin-8, Pentraxin-3, 
and Monocyte chemotactic protein-1 (see Table 2). In diabetic patients, leukocytes are 
more rigid and a higher proportion than usual are activated; increased retinal leukostasis 
results in capillary non-perfusion, endothelial cell damage, and vascular leakage via 
generation of toxic superoxide radicals and proteolytic enzymes [19, 20]. 
3. Bevacizumab for DME
Bevacizumab is a full-length (149 kDa) recombinant humanized monoclonal 
IgG1 antibody that binds all isoforms of VEGF-A [21]. It was originally approved for the 
treatment of metastatic colorectal cancer, but was first used off-label in 2005 for the 
treatment of exudative age-related macular degeneration (AMD). Its off-label use has 
been expanded to treat macular edema due to venous occlusions, as well as DME. It is the 
most cost-effective anti-VEGF option [22] and hence the first option considered for many 
patients. The BOLT study was a randomized prospective clinical trial of 80 patients with 
center-involving DME who had received at least one prior laser treatment; subjects were 
randomly assigned to receive either 1.25 mg bevacizumab injections (3 initial injections 
every 6 weeks with possible further injections guided by an optical coherence 
tomography (OCT)-based protocol) or additional modified ETDRS macular laser therapy 
(examination every 4 months with re-treatment as warranted by ETDRS guidelines) [12]. 
At 12 month follow up, the bevacizumab group had best-corrected visual acuity (BCVA) 
improve by a median of 8 ETDRS letters, compared to a loss of 0.5 letters in the laser 
group (p = 0.0002). The central subfield thickness (CSFT) improved by a mean of 129 
μm, compared to only 68 μm in the laser group. Bevacizumab continued to show superior 
BCVA and anatomic results compared to laser at 24 month follow up, with the 
6bevacizumab group showing a mean gain of 8.6 letters versus loss of 0.5 letters for laser, 
and reduction of CSFT by 146 μm compared to only 118 μm for laser [13]. 
The Pan-American Collaborative Retina Study Group retrospectively studied the 
efficacy of 1.25 mg vs 2.5 mg bevacizumab doses for diffuse DME. At 24 month follow 
up and after a mean of 5.8 (range 1-15) injections, the mean BCVA improved from 
20/150 to 20/75 (p<0.0001), and mean CSFT decreased by 179 μm (p<0.0001) in the 
1.25 mg dose group. For the 2.5 mg group, BCVA improved from 20/168 to 20/118 
(p=0.02) and CSFT improved by 151 μm (p<0.0001). No statistically significant 
differences were found in CSFT or BCVA between the 1.25 and 2.5 mg bevacizumab 
groups [23]. 
4. Ranibizumab for DME
Ranibizumab, a smaller (48kDa) recombinant humanized monoclonal IgG1 
antibody fragment (Fab), was specifically manufactured for use in the eye (unlike 
bevacizumab), and inhibits all known isoforms of VEGF-A. This molecule lacks a 
fragment crystallizable (Fc) region, which allows for faster systemic clearance [24]. 
Ranibizumab was approved by the U.S. Food & Drug Administration (FDA) for DME in 
2012, based on Genentech’s Phase III trials, RIDE and RISE [25, 26].  These two 
identically-designed, parallel, double-masked, three-year clinical trials were sham-
treatment controlled for 24 months. A total of 759 patients were randomized into three 
groups to receive monthly treatment with 0.3 mg ranibizumab (n=250), 0.5 mg 
ranibizumab (n=252) or sham injection (control group, n=257). Beginning at three 
months, macular laser rescue treatment was made available to all patients, if needed, 
based on pre-specified criteria. After month 24, patients in the sham injection group were 
7eligible to receive monthly injections of 0.5 mg ranibizumab and all patients were 
followed and dosed monthly for a total of 36 months.   
Compared to controls, a significantly greater percentage of ranibizumab-treated 
patients were able to read at least three additional lines (15 letters) at 24 months (primary 
endpoint).  The number of ETDRS letters gained at 24 months follow up was 12.5, 11.9, 
and 2.6 in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, and sham groups, respectively 
(RISE). In RIDE, the number of letters gained was 10.9, 12, and 2.3 in the same order. 
Both ranibizumab dose groups showed similar reduction in CSFT that was superior to 
sham: RISE: 251 μm (0.3 mg ranibizumab), 253 μm (0.5 mg ranibizumab), and 133 μm 
(sham); RIDE: 260 μm (0.3 mg ranibizumab), 271 μm (0.5 mg ranibizumab), and 126 μm 
(sham).  
Patients in the sham group required more rescue laser treatments (1.8) compared 
to both ranibizumab  groups (0.8 each) by 24 month follow up [26] Additionally, in both 
studies, significantly more patients who received ranibizumab compared with sham 
injections achieved vision greater than or equal to 20/40 and reported greater 
improvements in their ability to perform vision-related daily activities such as reading 
and driving, compared to the sham group, based on composite responses to the 25- item 
National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25)[27]. The 36-
month results indicate that patients in the sham group, who were eligible to cross over to 
monthly 0.5 mg ranibizumab after 24 months, did not achieve the same degree of VA 
gains as those patients who were in the ranibizumab group. After 12 months of 
ranibizumab, the crossover group only gained 2.8 letters compared to 10.6 and 11.1 
letters in the 0.3 and 0.5 mg ranibizumab groups, respectively. This suggests that chronic 
8macular edema may lead to a certain amount of irreversible VA loss, despite the fact that 
these patients CSFT improved by only 20 μm less than the ranibizumab group [25]. 
The RESTORE study demonstrated superiority of ranibizumab alone or in 
combination with laser, compared to using laser monotherapy, as treatment options for 
DME. At 12 months, CSFT was reduced by 119 μm, 128 μm, and 61 μm in the 
ranibizumab monotherapy, ranibizumab + laser, and laser monotherapy groups, 
respectively (p<0.001). BCVA improved by 6.1, 5.8, and 0.9 letters in these groups by 12 
months, respectively (p<0.0001). Visual acuity gains were associated with significant 
gains on the VFQ-25 scores [28]. Ranibizumab combined with prompt or deferred laser 
was also found to be superior to laser monotherapy in DRCR.net Protocol I [7].   
5. Aflibercept for DME
In 2014, aflibercept (also known as VEGF Trap-EYE) was approved for the 
treatment of DME.  Aflibercept is a recombinant fusion protein that is composed of the 
second extracellular binding domain from human VEGFR-1 and the third binding domain 
fromVEGFR-2 fused to the Fc domain of human immunoglobulin G1 molecule; it 
inhibits VEGF-A, VEGF-B and placental growth factor (PlGF) [21]. Regeneron’s Phase 
3 VISTA-DME and VIVID-DME studies of 862 patients compared aflibercept 2 mg 
given monthly (2q4), aflibercept 2 mg given every two months (2q8 after five initial 
monthly injections), or macular laser photocoagulation (at baseline and then as needed) 
[29, 30].  
In the VISTA 52 week follow up, the 2q4 and 2q8 aflibercept dosing groups 
gained 12.5 and 10.7 ETDRS letters, respectively, compared to only 0.2 letters in the 
9laser group (p<0.0001). In VIVID, the 2q4 and 2q8 groups gained 10.5 and 10.7 letters 
versus only 1.2 letters in the laser group (p<0.0001). The anatomic reduction in CSFT 
was similar for both dosing regimens in VISTA: 186 μm (2q4) and 183 μm (2q8) 
compared to only 73 μm in laser. For VIVID, the difference between aflibercept and laser 
was even more pronounced, with 2q4 and 2q8 groups reducing CSFT by 195 μm and 192 
μm, respectively, compared to only 66 μm for laser. Additional rescue laser was given to 
fewer eyes in the 2q4 and 2q8 groups (0.7% and 2.6% for VISTA and 4.4 and 8.1% for 
VIVID) compared to the laser group (31.2% for VISTA and 24.1% VIVID). A greater 
proportion of eyes in VISTA had previously received anti-VEGF injections (43% vs 9%) 
[31].  
The 100-week VIVID and VISTA results were recently published, and they report 
sustained superiority of aflibercept over laser. In VIVID, there were 11.5, 11.1, and 0.9 
letter gains in the 2q4, 2q8, and laser groups, respectively. In VISTA, there were 11.4, 
9.4, and 0.7 letter gains for the same groups [29]. The FDA-approved dosing for 
aflibercept is 2 mg every 2 months following 5 initial monthly injections. It also may be 
dosed once per month, but as the studies suggest, additional benefit was limited with this 
dosing plan. Analysis of eyes with CSFT reduction of <10% by week 12 indicated that 
these eyes generally underperformed compared to the entire cohort. By week 52, the 2q4, 
2q8, and laser groups had gains of 8.2, 10.5, and -2.6 letters in VISTA, and 7.4, 10.9, and 
0.8 letters in VIVID. The corresponding gains at week 100 were 6.6, 7.6, and -2.0 letters 
in VISTA, and 9.6, 8.1 and -0.1 letters in VIVID (Boyer DS, presented at Retina Society, 
Paris, France, October 8, 2015).  
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6. Comparing Anti-VEGF Options in DME
While the above mentioned studies show clear cut superiority of anti-VEGF 
treatments compared to laser for center-involving DME, there are not many large scale 
prospective studies comparing the efficacy of the anti-VEGFs to one another. On quick 
glance at the numbers reported in the aforementioned studies, it suggests that aflibercept 
and ranibizumab may be more effective than bevacizumab at reducing CSFT and 
improving BCVA. However, there are limitations in comparing numbers between 
separate studies with different treatment strategies and patient populations, especially 
given that the BOLT study was much smaller than RISE/RIDE and VIVID/VISTA. It is 
best to compare the anti-VEGF agents directly in a trial. 
 This issue was addressed by the National Institutes of Health (NIH) sponsored, 
Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness 
study in patients with Diabetic Macular Edema (Protocol T). Aflibercept was compared 
to ranibizumab and bevacizumab for the treatment of DME in this study. Six hundred and 
sixty patients were randomized to receive either aflibercept 2 mg, bevacizumab 1.25 mg, 
or ranibizumab 0.3 mg dosed according to a protocol-specified algorithm. Anti-VEGF 
treatment within 12 months was exclusionary. Patients were treated with focal/grid laser 
at or after the 24 week visit if: 1) the OCT central subfield thickness was greater than or 
equal to 250 microns or there was edema that was threatening the fovea and 2) the eye 
did not improve on OCT or visual acuity from the last two consecutive injections [32].  
In DRCR Protocol T, aflibercept demonstrated a significantly greater 
improvement in mean visual-acuity letter score at 52 weeks compared to both 
bevacizumab and ranibizumab injection in the subgroups with baseline ETDRS visual 
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acuity of 20/50 or worse (gain of 13.3, 9.7, and 11.2 letters in each group, respectively; p 
<0.0001 for aflibercept vs. bevacizumab; p = 0.03 for aflibercept vs. ranibizumab). There 
was no significant difference in visual acuity between the subgroups with better baseline 
visual acuity between 20/32 -20/40 (mean improvement of 8.0, 7.5, and 8.3 letters for 
aflibercept, bevacizumab, and ranibizumab, respectively; p>0.50 for each pairwise 
comparison). Anatomically, aflibercept and ranibizumab demonstrated a statistically 
significant greater reduction of CSFT compared to bevacizumab, with values of -169 μm, 
-147 μm, and -101 μm, respectively (p<0.001 for aflibercept and ranibizumab vs. 
bevacizumab; p = 0.036 for aflibercept vs. ranibizumab). These results held true 
regardless of initial baseline BCVA. The median number of injections using the protocol-
specified retreatment regimen was one fewer in patients treated with aflibercept (9 
injections) compared to bevacizumab and ranibizumab (10 injections each, p =0.045 for 
overall comparison). Fewer patients in the aflibercept group (37%) received criteria-
based macular laser treatments than those treated with bevacizumab (56%) and 
ranibizumab (46%, p<0.001 for overall comparison) [32]. These results allow one to 
speculate that either aflibercept or ranibizumab would be of potential benefit for treating 
persistent DME after trial with bevacizumab, though one must keep in mind that the 
subjects had not received anti-VEGF injections for at least 12 months prior to the study. 
Furthermore, the rates of most ocular and systemic adverse events (AEs) were 
similar across the three study groups. The rates of arterial thromboembolic events (ATE) 
as defined by the Anti-Platelet Trialists' Collaboration (non-fatal stroke, non-fatal 
myocardial infarction, and vascular death) in the trial were 3% in the aflibercept group, 
4% in the bevacizumab group, and 5% in the ranibizumab group (p =0.56). There were 
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more overall cardiovascular events in the ranibizumab group, compared to the aflibercept 
group and the bevacizumab group (p <0.01); this included more cardiac events and 
cerebrovascular events in the ranibizumab group [32]. A recent Cochrane review did not 
find any difference between bevacizumab and ranibizumab in terms of all-cause death, all 
serious systemic adverse events, ATE, myocardial infarction, or stroke. There was a 
higher incidence of gastrointestinal disorders associated with bevacizumab treatment 
(relative risk 1.82) [33]. 
7. Switching Anti-VEGF Therapy for Refractory DME
For DME patients who do not respond well to repeated injections of intravitreal 
bevacizumab, the clinician has the option to try other anti-VEGFs, corticosteroids, or 
macular laser. Evaluation with OCT may help identify other causes of macular edema, 
such as vitreomacular traction, which may warrant surgical treatment. Fluorescein 
angiogram can also be used adjunctively to identify focal areas of leakage from 
microaneursyms, which may be amenable to laser treatment. As of now, no large 
randomized prospective clinical trials comparing treatment regimens for refractory DME 
have been published, but several smaller uncontrolled studies can provide some insight.   
The REEF study (12 month prospective nonrandomized trial of 43 patients) found 
benefit in switching from bevacizumab to three monthly injections of 0.5 mg 
ranibizumab in patients with residual macular edema (CSFT >300 μm). Prior to the 
switch, patients had been treated with a mean of 4.7 bevacizumab injections with mean 
CSFT of 500 μm. Switching to ranibizumab resulted in additional reduction of 113 μm 
and 165 μm at 3 and 6 month follow up, respectively, with gains of 6.6 and 8.8 letters of 
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BCVA during the same time frames. Moreover, the 6/29 (20%) patients that did not 
respond adequately with ranibizumab 0.5 mg (CSFT reduction <10%) were switched to 
higher doses of three monthly 2.0 mg ranibizumab injections, which resulted in CSFT 
reduction >10% in 3 of 6 patients. Of note, the 2.0 mg dose of ranibizumab is not 
commercially available at this time [34]. 
Ciulla et al perfomed a retrospective review of 33 eyes with refractory DME that 
had been previously received an average of 5.1 treatments, including bevacizumab, 
triamcinolone, or macular laser. Switching to ranibizumab resulted in a statistically 
significant improvement in CSFT (from 384 μm to 335 μm), and BCVA (from 20/100 to 
20/90) after an average of 7 injections over 48 week follow up. Statistical significance 
was achieved in relation to number of days follow up, but not for number of ranibizumab 
injections [35]. 
Lim et al performed a retrospective review of 21 eyes treated for DME that were 
unresponsive to either bevacizumab or ranibizumab (mean of 6 treatments), that were 
then converted to a median of 3 aflibercept injections and followed over a median of 5 
months.  CSFT improved significantly from 453 μm to 363 μm (-90 μm) after the first 
injection, and was 324 μm (-129 μm) at last follow up. BCVA improved significantly 
from logMAR 0.42 to 0.39 after one aflibercept, and then 0.37 logMAR at last follow up 
[36]. Wood et al reported that 11 of 14 (79%) eyes with persistent DME despite at least 3 
injections of either bevacizumab or ranibizumab showed anatomic improvement after 
switching to aflibcercept; there was a 23% reduction of CSFT from 425 μm to 325 μm 
after 1 month (p<0.0132) [37]. Only 3 of 14 (21%) eyes had improved BCVA however. 
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8. Corticosteroids versus Anti-VEGF for DME
Chronic DME may differ even more in pathophysiology from non-chronic DME 
[38]. Anti-VEGF therapy may not be effective in all patients, because targeting VEGF 
does not suppress all the inflammatory cytokines and chemokines involved in DME.  
More recently, there has been interest in intravitreal corticosteroids, as the 
dexamethasone intravitreal implant  (DEX) [39] and the fluocinolone acetonide implant 
(FA) [40, 41] have been approved for the treatment of DME in 2014. There are few large 
prospective clinical trials comparing anti-VEGF agents to corticosteroids as first line 
therapy in center-involved DME, but DEX and FA implants could become early 
treatment for pseudophakic patients particularly. DRCR protocol I compared 0.5 
mg ranibizumab to 4 mg intravitreal triamcinolone acetonide; when analysis was 
confined to the pseudophakic group of patients to control for the effect of cataract 
formation, the group that received intravitreal triamcinolone acetonide plus prompt laser 
showed similar visual acuity results to the group that received ranibizumab plus prompt 
laser, as both groups gained a mean of 8 letters by 12 month follow up.[42].   
In June 2014, the U.S. FDA approved a 0.7 mg dexamethasone implant (DEX) 
contained in a solid bioerodable polymer for the use in DME in pseudophakic patients or 
those phakic patients scheduled for cataract surgery.  In September 2014, approval was 
expanded for the use in general DME patients, both pseudophakic and phakic, based on 
results of the MEAD study. After 3 years follow up, in which a mean of 4.1 DEX 
implants (0.7 mg) were administered, the DEX group experienced a mean CSFT 
reduction of 112 μm compared to 42 μm in the sham group. 22% of DEX 0.7 mg implant 
treated patients gained >15 letters BCVA compared to 12% in the sham group (p<0.108). 
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59% of the DEX 0.7 mg implant required cataract surgery compared to 7% in the sham 
group. 32% of the DEX group experienced IOP elevation ≥ 25 mmHg, 42% required 
IOP-lowering medications, and 0.6% required glaucoma incisional surgery [39]. 
 The BEVORDEX study was a randomized prospective trial comparing 
bevacizumab every 4 weeks to DEX every 16 weeks in 88 eyes with center-involving 
eyes with DME. At 12 months, 40% of bevacizumab-treated patients gained 10 or more 
letters of BCVA, compared to 41% in eyes that received DEX, although 11% of DEX-
treated eyes lost 10 or more letters of BCVA due to cataract formation. The DEX implant 
resulted in greater reduction of CSFT (-187 μm) than bevacizumab (-122 μm). The DEX 
group also received fewer injections (2.7) than the bevacizumab group (8.6) over the 
course of 12 months [43]. Maturi et al. compared efficacy of combination therapy with 
DEX and bevacizumab vs. continued bevacizumab monotherapy in 40 eyes that had 
refractory DME after multiple bevacizumab injections. The combination group received 
bevacizumab at baseline, and then DEX at months 1, 5, and 9. They also received 
bevacizumab as needed for CSFT >250 or ETDRS VA less than 80 letters. After 12 
months, compared to continued monthly bevacizumab monotherapy, the combination 
group had greater reduction of CSFT (-45 μm vs -30 μm, p =0.03), though VA 
improvement was not statistically significant for the combination group (combined 
group: +5.4 letters, bevacizumab: +4.9 letters, p=0.75). The combined group needed 3 
fewer bevacizumab injections, though this was counterbalanced by the need for a mean of 
2.1 DEX injections [44]. 
 A recent study compared the efficacy of fluocinolone acetonide (FA) sustained 
release implant in chronic (≥3 years duration) versus nonchronic (<3 years duration) 
16
DME, as part of a preplanned subgroup analysis of the FAME trial. The non-erodable FA 
implant releases the drug for up to 36 months. At month 36, the difference between FA 
implant and sham control in the percentage of subjects who gained 15 letters or more was 
significantly greater in 536 chronic DME subjects (34.0% vs. sham, 13.4%; P<0.001), 
compared to the 416 subjects with nonchronic DME (22.3% vs. sham, 27.8%; P = 0.275). 
The differences could not be explained by baseline ocular characteristics, changes in 
anatomic features, or differences in re-treatment or ancillary therapies. The authors 
speculate that early DME is driven primarily by VEGF, while chronic DME may be 
driven more by inflammatory cytokines in addition to anatomic changes, and that 
intravitreal corticosteroids will inhibit the release of these inflammatory cytokines [38]. 
The results suggest that the FA implant may be an option for patients who do not respond 
to other therapy. This report may also partially account for the clinical observations of 
beneficial effect using the DEX implant when anti-VEGF agents have minimal effect. 
Corticosteroid-related side effects were noted in the FAME study. Incisional 
glaucoma surgery was required by 4.8% of patients in the 0.2 μg/day (low dose FA) 
group and 8.1% of patients in the 0.5 μg/day (high dose FA) group. Cataracts progressed 
in nearly all phakic eyes. In September 2014, the FDA approved FA implant containing 
0.19 mg fluocinolone for DME in patients who have been previously treated with a 
course of corticosteroids and did not have a clinically significant rise in intraocular 
pressure.  However, this previous course of corticosteroids was not specified.  Clinicians 
could conceivably trial a topical corticosteroid, intravitreal bolus therapy with 
triamcinolone, or DEX implant.  
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9. Conclusion
In summary, anti-VEGF therapy is the new treatment of choice for center-
involved DME, as many studies have shown that it is superior compared to macular laser 
photocoagulation. Bevacizumab continues to be the most widely utilized anti-VEGF 
agent due to its cost-effectiveness. Recent data suggests that aflibercept is the most potent 
anti-VEGF treatment for DME, particularly in patients with ETDRS BCVA worse than 
20/40 [32]. Smaller studies have demonstrated anatomic and functional benefit in 
switching to ranibizumab [34] or aflibercept [36] when initial treatment with 
bevacizumab fails. Ongoing studies are exploring the efficacy of combining anti-VEGF 
treatment with sustained-release corticosteroids to treat DME. 
10. Expert Opinion
Despite growing clinical research data to support the use of anti-VEGF agents to 
treat DME, numerous questions remain.  Most clinicians do not follow dosing regimens 
employed in registration trials, as many will follow an off-label “treat and extend” 
regimen, which has not been studied in large randomized clinical trials. Furthermore, it is 
unclear if there is as much a need to “treat until absolutely dry” as in exudative AMD.  
Many clinicians will switch between agents when there is suboptimal response; however, 
there is no consensus on the definition of suboptimal response or the definition of an 
appropriate trial of one agent before switching to another. One recent analysis of 
refractory DME cases from the VIVID/VISTA trials considered refractory DME to be 
<10% CSFT reduction after 12 weeks (Boyer DS, presented at Retina Society, Paris, 
France, October 8, 2015). We believe that a 12-week time frame and minimum of 3 anti-
VEGF injections is a reasonable cutoff for defining refractory DME. 
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There are multiple controversial issues surrounding bevacizumab and other 
agents.  Proponents of bevacizumab cite large cost disparities between bevacizumab 
($50), ranibizumab 0.3 mg ($1170) and aflibercept ($1850), while others note that patient 
assistance programs are readily available to assist underinsured patients and potentially 
limit financial risk for physician practices.  Furthermore, bevacizumab is used off-label, 
as it is repackaged and resold by compounding pharmacies, around which there have 
been some sterility issues, leading to increased regulation and more laborious patient-
specific bevacizumab prescription requirements.  More recently, there has been cost 
profiling by insurance companies, which has likely led to the controversial narrowing of 
panels and/or being dropped by insurance networks. Finally, retina specialists assume 
public relations risk in being identified as a large consumer of Medicare funds, due in 
part to the expense of the FDA-approved anti-VEGF agents.   
The protocol-based ETDRS visual acuity used in DRCR Protocol T is often 
several lines better than the Snellen BCVA routinely obtained in the clinical setting, so 
the 20/50 cut off for treating with aflibercept may not directly translate to clinical practice. 
Adjusting for this, one may consider starting treatment with intravitreal bevacizumab for 
center-involved DME and only mild vision loss, especially when cost is an issue, as it has 
shown efficacy in reducing CSFT and improving BCVA. If CSFT or BCVA fails to 
improve after 2 bevacizumab injections, it may be prudent to switch to aflibercept or 
ranibizumab. One must also keep in mind that the strict monthly visits mandated in the 
clinical trials may not translate to clinical practice in the real world, where follow up may 
be less frequent and reliable, and with some patients being subsequently underdosed with 
anti-VEGF treatment. 
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While aflibercept was shown to be superior to ranibizumab in patients with 
ETDRS BCVA worse than 20/40 in DRCR Protocol T, these results may not apply to the 
population of refractory DME patients, whose pathophysiology could vary from those 
affected by treatment-naïve DME. As of now, one small retrospective series supports 
switching to aflibercept after patients have failed treatment with bevacizumab and 
ranibizumab, as it has been shown to result in statistically significant improvement in 
CSFT and BCVA [36]. Tachyphylaxis may partially explain the benefits achieved by 
switching from one anti-VEGF to another, as repeated doses of the same drug may result 
in diminishing effect. Larger prospective randomized clinical trials are needed to validate 
these findings. For those DME patients with ETDRS BCVA worse than 20/40, 
aflibercept is a first-line option, but its high cost continues to be a limiting factor for 
many patients despite the advantages of its 2-month injection frequency. 
For non-centered involved refractory DME, laser treatment could remain an 
effective treatment, since the risks of laser photocoagulation are minimal in these cases, 
compared to the risks, discomfort, and expense of intravitreal therapies. After a series of 
anti-VEGF injections, a deferred focal laser therapy to localized areas of microaneurysm 
formation may decrease the number of required subsequent injections. For center-
involved DME that is persistent despite periodic anti-VEGF therapy, the durable action 
of corticosteroid implants, such as the DEX and FA implants, facilitates combination 
therapy. The risks of sustained corticosteroid therapy, mainly glaucoma and cataract 
progression, should be carefully considered in the context of each patient. Pseudophakic 
patients, and those who have used a trial of corticosteroids without ocular hypertension, 
are preferred candidates for the DEX and FA implants. 
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Although the improvement in visual acuity and CSFT may seem modest after 
switching therapies, these cases of refractory DME can be especially difficult to treat, and 
consequently these modest improvements can be clinically meaningful, especially in 
patients with bilateral refractory DME.  Bevacizumab, ranibizumab, and aflibercept each 
have different molecular sizes, binding affinities for VEGF, as well as different half-lives 
in the vitreous, and this could account for some of the differences noted between these 
agents. Aflibercept is the only available treatment that targets placental growth factor, 
which has an unclear role in the pathogenesis of DR, but animal studies suggest that it 
may contribute to blood-retinal barrier breakdown [45, 46]. 
Combining anti-VEGF treatment with sustained-release corticosteroids is a 
promising area of future research, as this approach may allow for more extensive control 
of the complex inflammatory pathways involved in DME. The synergistic effect of 
sustained-release corticosteroids may result in fewer anti-VEGF injections needed to 
keep DME under control. Currently, the DRCR Protocol U is exploring the efficacy of 
combination therapy with 0.3 mg ranibizumab and dexamethasone intravitreal implant 
compared to continued therapy with 0.3 mg ranibizumab to treat persistent DME. The 
results of DRCR Protocol T suggest the need for large prospective randomized trials to 
validate that switching from either bevacizumab to ranibizumab or aflibercept is superior 
to continued bevacizumab treatment in cases of persistent DME. Further study of 
refractory DME is warranted, given the visual disability caused.  
Article Highlights Box  
• The complex pathophysiology of DME involves upregulation of VEGF and other
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inflammatory mediators. 
• Anti-VEGF agents are first-line treatment for center-involved DME.
Bevacizumab is a cost-effective and widely used anti-VEGF treatment, though
aflibercept is the most effective option in patients with BCVA worse than 20/40
using ETDRS protocol eye charts.
• Some cases of DME are refractory to multiple bevacizumab treatments, and small
studies report that switching to ranibizumab or aflibercept results in additional
improvement in BCVA and macular thickness
• Future research will focus on efficacy of combined anti-VEGF and sustained-
release corticosteroids to control refractory DME
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Table 1. Overview of select prospective randomized clinical trials regarding treatment of 
diabetic macular edema 
Study 
Name 
Format Anatomic Outcomes BCVA Outcomes 
READ-2 0.5 mg IVR  
vs. laser only  
vs. combination (1:1:1) 
Mean CSFT at 24 months: 
0.5 mg IVR: 340 μm 
laser only: 286 μm 
combination: 258 μm 
Mean BCVA change at 24 
months: 
0.5 mg IVR: +7.7 letters 
laser ony: +5.1 letters 
combination: +6.8 letters 
RESTORE 0.5 mg IVR  
vs. laser only  
vs. combination (1:1:1) 
Mean CSFT change at 12 
months: 
0.5 mg IVR: -119 μm 
laser ony: -61 μm 
combination: -128  μm 
Mean BCVA change at 12 
months: 
0.5 mg IVR: +6.1 letters 
laser ony: +0.8 letters 
combination: +5.9 letters 
RISE/RIDE 0.3 mg IVR  
vs. 0.5 mg IVR  
vs. sham (1:1:1) 
Mean CSFT change at 24 
months (RISE/RIDE): 
0.3 mg IVR: -251/-260 μm 
0.5 mg IVR: -253/-271 μm 
Sham: -133/-126 μm 
Mean CSFT change at 36 
months (RISE/RIDE): 
0.3 mg IVR: -261/ -262 μm
0.5 mg IVR: -269/ -267 μm
Sham: -200/-213 μm 
Mean BCVA change at 24 
months (RISE/RIDE): 
0.3 mg IVR: +12.5/+10.9 
letters 
0.5 mg IVR: +11.9/+12.0 
letters 
Sham: +2.6/+2.3 letters 
Mean BCVA change at 36 
months (RISE/RIDE): 
0.3 mg IVR: +15.6/+12.8 
letters 
0.5 mg IVR: +12.0/+13.0 
letters 
Sham: +7.6/+7.5 letters 
DRCR.net  
Protocol I 
Prompt laser only  
vs. 0.5 mg IVR + prompt laser 
vs. 0.5 mg IVR + deferred 
laser  
vs. 4 mg IVTA + prompt laser 
Mean CSFT change at 24 
months: 
0.5 mg IVR + prompt laser: 
-144 μm 
0.5 mg IVR + deferred 
laser: -170 μm 
4mg IVTA + prompt laser: 
-95 μm  
Sham + prompt laser: -133 
μm 
Mean CSFT change at 60 
months: 
0.5 mg IVR + prompt laser: 
-167 μm 
0.5 mg IVR + deferred 
laser: -165 μm 
Mean BCVA change at 24 
months: 
0.5 mg IVR + prompt laser: 
+7.0 letters 
0.5 mg IVR + deferred 
laser: +10.0 letters 
4mg IVTA + prompt laser: 
0.0 letters  
Sham + prompt laser: +2.0 
letters 
Mean BCVA change at 60 
months: 
0.5 mg IVR + prompt laser: 
+7.2 letters 
0.5 mg IVR + deferred 
laser: +9.8 letters 
BOLT 1.25 mg IVB  
vs. laser only (1:1) 
Mean CSFT change at 12 
months: 
1.25 mg IVB: -129 μm 
laser only: -68 μm 
Mean CSFT change at 24 
months: 
1.25 mg IVB: -146 μm
Median BCVA change at 12 
months: 
1.25 mg IVB: +8.0 letters 
laser only: -0.5 letters 
Mean BCVA change at 24 
months: 
1.25 mg IVB: +8.6 letters
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laser only: -118 μm laser only: -0.5 letters 
VIVID & 
VISTA 
IVA 2q4 
 vs. IVA 2q8 (after 5 monthly 
doses)  
vs. laser 
Mean CSFT change at 12 
months (VISTA/VIVID): 
IVA 2q4: -186/-195 μm 
IVA 2q8: -183/-192 μm 
laser: -73/-66 μm 
Mean CSFT change at 100 
weeks: 
IVA 2q4: -191.4/-211.8 μm
IVA 2q8: -191.1/-195.8 μm
laser: -83.9/-85.7 μm 
Mean BCVA change at 12 
months (VISTA/VIVID): 
IVA 2q4: +12.5/+10.5 
letters 
IVA 2q8: +10.7/+10.7 
letters 
laser: +0.2/+1.2 letters 
Mean BCVA change at 100 
weeks: 
IVA 2q4: +11.4/+11.5 
letters 
IVA 2q8: +9.4/+11.1 letters
laser: +0.7/+0.9 letters 
DRCR.net  
Protocol T 
IVA 2 mg  
vs. IVR 0.3 mg  
vs IVB 1.25 mg (1:1:1) 
Mean CSFT change at 12 
months: 
IVA 2 mg: -169 μm 
IVR 0.3 mg: -147 μm 
IVB 1.25 mg: -101 μm 
Mean BCVA change at 12 
months: 
IVA 2q4: +13.3 letters 
IVR 0.3 mg: +9.7 letters 
IVB 1.25 mg: +11.2 letters 
MEAD DEX 0.35 mg  
vs. DEX 0.7 mg  
vs. sham (1:1:1) 
Mean CSFT change at 36 
months: 
Dex 0.35 mg:-108 μm 
Dex 0.7 mg: -112 μm 
sham: -42 μm 
Mean BCVA change at 36 
months: 
Dex 0.35 mg: +3.6 letters 
Dex 0.7 mg: +3.5 letters 
sham: +2.0 letters 
FAME FA 0.2 μg/day  
vs. FA 0.5 μg/day  
vs. sham (2:2:1) 
Mean CSFT change at 24 
months: 
FA 0.2 μg/day: -177 μm 
FA 0.5 μg/day: -168 μm 
sham: -111μm 
Mean BCVA change at 24 
months: 
FA 0.2 μg/day: +4.4 letters 
FA 0.5 μg/day: +5.4 letters 
sham: +1.7 letters 
READ, Ranibizumab for Edema of the Macula in Diabetes; IVR, intravitreal 
ranibizumab; CSFT, central subfield thickness; BCVA, best corrected visual acuity; 
RESTORE, Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due 
to Diabetic Macular Edema; RISE/RIDE, Ranibizumab Injection in Subjects with 
Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes 
Mellitus; DRCR, Diabetic Retinopathy Clinical Research Network; IVTA, intravitreal 
triamcinolone acetonide; BOLT, Bevacizumab or Laser Therapy in the Management of 
Diabetic Macular Edema; IVB, intravitreal bevacizumab; VIVID/VISTA, Intravitreal 
Aflibercept Injection in Vision Impairment due to DME; FAME, Fluocinolone Acetonide 
for Diabetic Macular Edema; FA, fluocinolone acetonide 
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Table 2 
Inflammatory markers upregulated in DME 
Vascular Endothelial Growth Factor 
Interleukin-6 
Tumor necrosis factor-alpha 
Monocyte chemotactic protein-1 
Cyclooxygenase-2 
Pentraxin3 
Interleukin-8 
Intercellular Adhesion Molecule-1 
